Advisors Asset Management, Inc. Vertex Pharmaceuticals Inc Transaction History

Advisors Asset Management, Inc.

$5.28 Billion
Q3 2024

A detailed history of Advisors Asset Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 26,467 shares of VRTX stock, worth $13.7 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

26,467

Previous 23,108 14.54%

Holding current value

$13.7 Million

Previous $10.8 Million 13.65%

% of portfolio

0.23%

Previous 0.22%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$460.0 - $505.78 $1.55 Million - $1.7 Million	3,359 Added 14.54%	26,467 $12.3 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $677,204 - $837,053	1,724 Added 8.06%	23,108 $10.8 Million
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $1.49 Million - $1.63 Million	3,656 Added 20.62%	21,384 $8.94 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $720,986 - $863,249	2,102 Added 13.45%	17,728 $7.21 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $670,029 - $749,920	2,131 Added 15.79%	15,626 $5.5 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $484,040 - $552,177	1,709 Added 14.5%	13,495 $4.25 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $118,018 - $132,771	-413 Reduced 3.39%	11,786 $3.4 Million
Q3 2022 Nov 08, 2022	BUY	$273.83 - $305.53 $365,015 - $407,271	1,333 Added 12.27%	12,199 $3.53 Million
Q2 2022 Aug 08, 2022	SELL	$234.96 - $292.55 $1.17 Million - $1.46 Million	-5,000 Reduced 31.51%	10,866 $3.06 Million
Q1 2022 May 17, 2022	SELL	$221.42 - $260.97 $1.19 Million - $1.4 Million	-5,376 Reduced 25.31%	15,866 $4.14 Million
Q4 2021 Feb 15, 2022	SELL	$177.01 - $223.45 $789,110 - $996,140	-4,458 Reduced 17.35%	21,242 $4.67 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $356,794 - $399,281	-1,967 Reduced 7.11%	25,700 $4.66 Million
Q2 2021 Jul 30, 2021	SELL	$187.49 - $221.1 $579,719 - $683,641	-3,092 Reduced 10.05%	27,667 $5.58 Million
Q1 2021 May 07, 2021	BUY	$207.02 - $241.31 $539,080 - $628,371	2,604 Added 9.25%	30,759 $6.61 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $679,820 - $906,679	3,284 Added 13.2%	28,155 $6.65 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $180,233 - $213,685	705 Added 2.92%	24,871 $6.77 Million
Q2 2020 Aug 12, 2020	BUY	$225.48 - $295.8 $979,034 - $1.28 Million	4,342 Added 21.9%	24,166 $7.02 Million
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $572,540 - $710,223	2,866 Added 16.9%	19,824 $4.72 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $245,563 - $329,819	1,473 Added 9.51%	16,958 $3.71 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $169,887 - $191,205	-1,022 Reduced 6.19%	15,485 $2.62 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $594,571 - $687,616	-3,612 Reduced 17.95%	16,507 $3.03 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $420,622 - $500,184	2,569 Added 14.64%	20,119 $3.7 Million
Q4 2018 Jan 31, 2019	BUY	$151.91 - $192.21 $525,304 - $664,662	3,458 Added 24.54%	17,550 $2.91 Million
Q3 2018 Nov 15, 2018	SELL	$167.73 - $192.74 $225,093 - $258,657	-1,342 Reduced 8.7%	14,092 $2.72 Million
Q2 2018 Aug 22, 2018	SELL	$145.72 - $169.96 $514,683 - $600,298	-3,532 Reduced 18.62%	15,434 $2.62 Million
Q2 2018 Aug 15, 2018	BUY	$145.72 - $169.96 $907,252 - $1.06 Million	6,226 Added 48.87%	18,966 $2.62 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $97,024 - $113,363	-640 Reduced 4.78%	12,740 $2.12 Million
Q4 2017 Feb 13, 2018	BUY	$137.28 - $155.55 $20,454 - $23,176	149 Added 1.13%	13,380 $2.01 Million
Q3 2017 Nov 07, 2017	BUY	$148.13 - $162.24 $1.96 Million - $2.15 Million	13,231	13,231 $2.01 Million

Others Institutions Holding VRTX

# of Institutions

1,717

Shares Held

226M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $133B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.

Account

Advisors Asset Management, Inc. Vertex Pharmaceuticals Inc Transaction History